Last reviewed · How we verify

YAZ (SH T00186D) — Competitive Intelligence Brief

YAZ (SH T00186D) (YAZ (SH T00186D)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: estrogen-progestin combination. Area: Women's Health.

phase 3 estrogen-progestin combination Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

YAZ (SH T00186D) (YAZ (SH T00186D)) — Bayer. YAZ is a combination oral contraceptive that contains drospirenone and ethinyl estradiol, which work to prevent ovulation and pregnancy.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
YAZ (SH T00186D) TARGET YAZ (SH T00186D) Bayer phase 3 estrogen-progestin combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (estrogen-progestin combination class)

  1. Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). YAZ (SH T00186D) — Competitive Intelligence Brief. https://druglandscape.com/ci/yaz-sh-t00186d. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: